Articles tagged "Hepatitis C"

2017 American Transplant Congress
Use of Ledipasvir/Sofosbuvir with or without Ribavirin in Patients Post-Liver Transplant: Evaluation of Real-World Datasets.
S. Flamm,¹ M. Charlton,² M. Manns,³ M. Prieto,⁴ I. Fernandez,⁵ M. Londono,⁶ R. Kwok,⁷ C. Smith,⁸ S. Lee,⁹ H. Ngo,⁹ A. Osinusi,⁹ A. Copans,⁹ L. Rossaro,⁹ M. Shoreibah,¹⁰ O. Massoud,¹⁰ M. Curry,¹¹ M. Bourliere.¹²
¹Northwestern University, Chicago; ²Intermountain Medical Center, Murray; ³Hannover Medical School, Hannover, Germany; ⁴Hospital Universitari I Politecnic La Fe, Valencia, Spain; ⁵Hospital Universitario 12 de Octubre, Madrid, Spain; ⁶Servicio de Hepatología. Hospital Clinic, Barcelona, Spain; ⁷Walter Reed National Military Medical Center, DC; ⁸Medstar Georgetown University Hospital, Georgetown; ⁹Gilead Sciences, Inc., Foster City; ¹⁰University of Alabama Birmingham, Birmingham; ¹¹Beth Israel Deaconess Medical Center, Boston; ¹²Hospital Saint Joseph, Marsielle, France
PURPOSE: Post-liver transplant(LT) patients with HCV are considered a difficult-to-treat population. Ledipasvir/sofosbuvir(LDV/SOF) +ribavirin(RBV) for 12 weeks is approved in GT1 LT recipients based on the…
2017 American Transplant Congress
Willingness of End-Stage Renal Disease Patients (ESRD) without Hepatitis C (HCV) to Accept a HCV+ Kidney.
P. Reese,¹ D. Goldberg,¹ A. Mussell,¹ M. McCauley,¹ D. Sawinski,¹ N. Molina,² R. Tomlin,² S. Doshi,¹ P. Abt,¹ E. Blumberg,¹ C. Thiessen,² S. Kulkarni,² G. Esnaola.²
¹UPENN, Philadelphia, PA; ²Yale, New Haven, CT
Background: New HCV drugs could reduce the risks of donor-derived HCV infection. However, it is unknown if HCV-negative (HCV-) ESRD patients would accept an HCV+…
2017 American Transplant Congress
The Safety and Efficacy of Directly-Acting Antivirals with or without Ribavirin for HCV Genotype 1 Infection: A Systematic Review and Meta-Analysis.
Z. Guo, J. Gu, X. He, G. Chen.
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Previous studies have reported that ribavirin-free regimens are effective for treating chronic hepatitis C virus genotype 1 infection. However, the efficacy and safety of ribavirin-free…
2017 American Transplant Congress
Ambiguous Nucleic Acid Tests (NAT) Results – Case of a Donor with Intermittent HCV NAT(+) but No HCV Transmission.
M. Nowicki,^1,2 H. Prince,² C. Chinchilla,² C. De Los Santos,² J. Trageser,³ L. Stocks.³
¹Mendez National Institute of Transplantation Foundation, Los Angeles, CA; ²VRL-Eurofins, Los Angeles, CA; ³Lifesharing OPO, San Diego, CA
Background Less than 0.2 % of initially NAT(+) upon retesting are reported as NAT negative. However, there is a concern that these results could be…
2017 American Transplant Congress
Direct Acting Antiviral Drugs Are Highly Effective in Hepatitis C (HCV) Patients with End Stage Renal Disease (ESKD) and Advanced Liver Disease (ALD).
J. Korula, T. Shah, E. Ranger, E. Barba, D. Vu, R. Naraghi.
Multi Transplant Organ Center, St Vincent Medical Center, Los Angeles, CA
Reports of efficacy of Direct Acting Antiviral drugs (DAA) > 90% in treatment of chronic HCV genotype 1, [GT1, 12 wk Sustained Viral Response (SVR12)]…
2017 American Transplant Congress
Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients.
K. Nadhan, E. Usedom, S. Shipman, A. Doyle, G. Malat, E. Buchanan, C. Chung.
Dermatology, Drexel, Philadelphia
Purpose: HIV and HCV are two immune dysregulatory processes that may exacerbate the risk of nonmelanoma skin cancer (NMSC) in organ transplant recipients (OTR), a…
2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
S. Kilaru,¹ E. Tapper,² M. Curry.³
¹Medicine, NYU School of Medicine, New York, NY; ²Medicine, University of Michigan, Ann Arbor, MI; ³Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…
2017 American Transplant Congress
A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.
N. Kapila,¹ B. Zervos,² B. Ismail,¹ G. Schnickel,² J. Rivas,² D. Reino,² N. Agrawal,² A. Tzakis.²
¹Gastroenterology/Hepatology, Cleveland Clinic, Weston, FL; ²Transplant, Cleveland Clinic, Weston, FL
Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…
2017 American Transplant Congress
A Multi-Center Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving HCV Positive Livers.
N. Kapila,¹ B. Zervos,² B. Ismail,¹ C. Lindenmeyer,³ V. Sanghi,³ K. Menon,³ G. Schnickel,² J. Rivas,² D. Reino,² A. Tzakis.²
¹Gastroenterology, Cleveland Clinic, Weston, FL; ²Transplant, Cleveland Clinic, Weston, FL; ³Gastroenterology, Cleveland Clinic, Cleveland, OH
Background: HCV cirrhosis is the leading indication for liver transplantation in the U.S. The development of direct acting anti-viral agents (DAAs) has changed the approach…
2017 American Transplant Congress
Hepatitis C Genotypes Among Deceased Organ Donors in the United States.
D. Goldberg,¹ V. Van Deerlin,¹ M. Farooqi,¹ A. Sicilia,¹ R. Hasz,² R. Bloom,¹ E. Blumberg,¹ C. Gentile,¹ P. Abt,¹ P. Reese.¹
¹University of Pennsylvania, Philadelphia, PA; ²Gift of Life, Philadelphia, PA
Background: HCV is one of the leading causes of liver disease in the US. 5% of deceased organ donors are HCV+ and HCV infection is…